Switch theme
Sign up to access all valuation multiples
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
1942
81K+
LTM Revenue $63.1B
LTM EBITDA $24.4B
$178B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pfizer has a last 12-month revenue (LTM) of $63.1B and a last 12-month EBITDA of $24.4B.
In the most recent fiscal year, Pfizer achieved revenue of $63.6B and an EBITDA of $18.1B.
Pfizer expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pfizer valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $63.1B | XXX | $63.6B | XXX | XXX | XXX |
| Gross Profit | $47.1B | XXX | $45.8B | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $24.4B | XXX | $18.1B | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $21.8B | XXX | $14.9B | XXX | XXX | XXX |
| EBIT Margin | 34% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $17.5B | XXX | $8.0B | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $62.6B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pfizer's stock price is $23.
Pfizer has current market cap of $134B, and EV of $178B.
See Pfizer trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $178B | $134B | XXX | XXX | XXX | XXX | $3.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pfizer has market cap of $134B and EV of $178B.
Pfizer's trades at 2.8x EV/Revenue multiple, and 9.8x EV/EBITDA.
Equity research analysts estimate Pfizer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pfizer has a P/E ratio of 7.6x.
See valuation multiples for Pfizer and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $134B | XXX | $134B | XXX | XXX | XXX |
| EV (current) | $178B | XXX | $178B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 7.3x | XXX | 9.8x | XXX | XXX | XXX |
| EV/EBIT | 8.2x | XXX | 11.9x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 7.6x | XXX | 16.6x | XXX | XXX | XXX |
| EV/FCF | 12.6x | XXX | 18.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPfizer's last 12 month revenue growth is -1%
Pfizer's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.4M for the same period.
Pfizer's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pfizer's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pfizer and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | 61% | XXX | XXX | XXX |
| Rule of 40 | 15% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pfizer acquired XXX companies to date.
Last acquisition by Pfizer was XXXXXXXX, XXXXX XXXXX XXXXXX . Pfizer acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pfizer founded? | Pfizer was founded in 1942. |
| Where is Pfizer headquartered? | Pfizer is headquartered in United States of America. |
| How many employees does Pfizer have? | As of today, Pfizer has 81K+ employees. |
| Who is the CEO of Pfizer? | Pfizer's CEO is Dr. Albert Bourla, D.V.M.,PhD. |
| Is Pfizer publicy listed? | Yes, Pfizer is a public company listed on NYS. |
| What is the stock symbol of Pfizer? | Pfizer trades under PFE ticker. |
| When did Pfizer go public? | Pfizer went public in 1951. |
| Who are competitors of Pfizer? | Similar companies to Pfizer include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Pfizer? | Pfizer's current market cap is $134B |
| What is the current revenue of Pfizer? | Pfizer's last 12 months revenue is $63.1B. |
| What is the current revenue growth of Pfizer? | Pfizer revenue growth (NTM/LTM) is -1%. |
| What is the current EV/Revenue multiple of Pfizer? | Current revenue multiple of Pfizer is 2.8x. |
| Is Pfizer profitable? | Yes, Pfizer is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pfizer? | Pfizer's last 12 months EBITDA is $24.4B. |
| What is Pfizer's EBITDA margin? | Pfizer's last 12 months EBITDA margin is 39%. |
| What is the current EV/EBITDA multiple of Pfizer? | Current EBITDA multiple of Pfizer is 7.3x. |
| What is the current FCF of Pfizer? | Pfizer's last 12 months FCF is $14.1B. |
| What is Pfizer's FCF margin? | Pfizer's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of Pfizer? | Current FCF multiple of Pfizer is 12.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
